IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the six months ended June 30, 2023, as well as operational and recent corporate developments.
Physician Interest and Adoption of ProSense in the U.S. Builds Momentum as ProSense is Featured at Medical Conferences and Educational Courses ProSense was the.
Rising Utilization of ProSense in the U.S. Market Generates Year-over-Year Consumable Revenue Growth Physician Adoption Continues to Grow Ahead of the FDA s.
IceCure Medical Reports 2022 Full Year Financial Results & Recent Corporate Developments; Milestone Achievements Expected to Drive Revenue Growth in 2023 - read this article along with other careers information, tips and advice on BioSpace
IceCure Medical, BrainStorm Cell Therapeutics, and NeuroSense Therapeutics are three Israeli medtech firms that all made new moves this week. BrainStorm Cell Therapeutics Inc., a developer of adult stem cell therapeutics for neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) will hold an Advisory Committee Meeting (‘ADCOM’) to discuss the company’s Biologics […]